Ottobock stock: Goldman reassesses valuation after Q3 update

Published on 11/13/2026 at 18:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ottobock stock draws a fresh Goldman Sachs assessment after its third-quarter update. The bank sees reimbursement risks but considers the valuation contraction excessive.

What Goldman changed

Goldman Sachs considers Ottobock's post-Q3 valuation contraction excessive despite reimbursement risks.
The company kept its 2026 outlook while pointing to slower revenue conversion in parts of the business.
Ottobock stock was last quoted at 39.93 euros on Lang & Schwarz on Friday, November 13.

Ottobock, DE000BCK2223, Illustration mit AI erstellt.

Goldman Sachs has reassessed Ottobock after the medical technology group released its third-quarter and nine-month results on Thursday, November 12. In research published on Friday, November 13, the bank said the valuation contraction following the update looked excessive, while still lowering estimates to reflect reimbursement pressure.

Goldman reframes the Q3 response

According to Goldman Sachs research, Ottobock's third-quarter organic core revenue growth was 6.4 percent, down from 8.1 percent in the second quarter. The bank described the result as broadly in line with expectations and highlighted a further improvement in core EBITDA margin to 27.7 percent.

Goldman Sachs said Ottobock was trading at 11.6 times next-twelve-month earnings on its revised estimates. The bank reduced its estimates for 2026 core revenue, EBITDA and earnings per share by between zero and 1 percent, indicating a limited adjustment to its operating assumptions.

Reimbursement remains the key risk

The main concern is the changing reimbursement environment. Goldman Sachs cited longer approval cycles in several markets and a 3 percent price reduction in Germany scheduled to begin in January. These developments can delay the conversion of patient demand into reported revenue, particularly in business areas exposed to reimbursement approvals.

Ottobock has confirmed its 2026 target for organic core revenue growth of 6.0 to 8.0 percent and an underlying core EBITDA margin above 27.0 percent. Management expects a more moderate seasonal contribution in the fourth quarter, while 2027 guidance is due with the full-year 2026 results in March 2027.

Ottobock stock was last quoted at 39.93 euros on Lang & Schwarz at 18:07:51 CET on Friday, November 13, 2026.